Has Griffith Evans, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,662 in general payments to Griffith Evans, MD across 90 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Griffith Evans, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Griffith Evans, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Griffith Evans, MD

Pain Medicine · Omaha, NENPI 1730137761

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Abbott at 31.7% of the total. Reporting peaked in 2019 at $700 and has fallen 76.0% since, to $168 in 2025. That places this record below the midpoint for pain medicine clinicians in NE, where the typical reported total is $4,468.

$2,662in general payments, 2019–2025

Across 90 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$844
Medtronic$492
Boston Scientific$288
AbbVie$258
Nevro Corp.$92
Lilly USA, LLC$72
plus $616 from 19 others

What the payments were for

Food & beverage$2,662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	16	$844
Medtronic(2 entities)	10	$492
Boston Scientific	16	$288
AbbVie(2 entities)	14	$258
Nevro Corp.	3	$92
Lilly USA, LLC	4	$72
Vertos Medical, Inc.	1	$63
SPR Therapeutics, Inc	2	$57
Si-bone, Inc.	3	$51
Spinal Simplicity, LLC	1	$51
Pacira Pharmaceuticals Incorporated	2	$46
Stryker	1	$40
Biodelivery Sciences International, Inc.	3	$39
Baudax Bio Inc.	2	$36
Vertex	2	$33
Biohaven Pharmaceutical Holding Company Ltd.	1	$28
Biotronik NRO, Inc.	1	$27
Lundbeck LLC	1	$26
Arbor Pharmaceuticals, Inc.	1	$21
Pfizer	1	$20
Nalu Medical, Inc.	1	$19
Relievant Medsystems, Inc.	1	$16
Forte Bio-pharma LLC	1	$15
MML US, Inc.	1	$14
Collegium Pharmaceutical, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,662 in reported general payments places this provider in the 35th percentile of 31 pain medicine providers in Nebraska.

See all pain medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024

$76,290

Medicare patients

131

Services billed

2,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	280	$7,030
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	105	$3,901
Buprenorphine	12	$3,676
Morphine Sulfate ErMorphine Sulfate	103	$3,004
Gabapentin	117	$2,028
Pregabalin	41	$1,912
Fentanyl	12	$1,271
Oxycodone Hcl	46	$996
Tizanidine Hcl	34	$543
Tramadol Hcl	78	$498
Duloxetine Hcl	27	$367
Nortriptyline Hcl	12	$253
Clonazepam	19	$217
Celecoxib	22	$200
Hydromorphone Hcl	12	$169

Paid to pharmacies, not to this prescriber.

Other pain medicine in Omaha

Matthew StottleOmaha$14K
Katie BerkyOmaha$12K
Tyrus SoaresOmaha$8K
Apollo StackOmaha$8K
Jess RolandOmaha$8K
Marshall LaddOmaha$7K
James DevneyOmaha$5K
Peter PiperisOmaha$4K
Dan NichollsOmaha$3K
Ernesto PadronOmaha$3K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →